11329

協賛企業

Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients.

著者 Naya M , Tsukamoto T , Morita K , Katoh C , Furumoto T , Fujii S , Tamaki N , Tsutsui H
J Am Coll Cardiol.2007 Sep 18 ; 50(12):1144-9.
この記事をPubMed上で見るPubMedで表示

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

(55view , 0users)
OBJECTIVES: We aimed to compare the effects of the angiotensin II receptor blocker (ARB) olmesartan versus the calcium channel blocker (CCB) amlodipine on coronary endothelial dysfunction in patients with hypertension. BACKGROUND: Angiotensin II receptor blockers are thought to have greater beneficial effects than CCBs on coronary vasomotion by directly blocking action of angiotensin II. METHODS: Twenty-six patients with untreated essential hypertension were prospectively assigned to treatment with either olmesartan (27.7 +/- 12.4 mg/day, n = 13) or amlodipine (5.6 +/- 1.5 mg/day, n = 13) for 12 weeks. Changes of corrected myocardial blood flow (DeltaMBF) and coronary vascular resistance (DeltaCVR) from rest to cold pressor were measured by using 15O-water and positron emission tomography before and after treatment. Blood biomarkers including lipids, glucose, insulin, high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and superoxide dismutase (SOD) were also measured. RESULTS: Olmesartan and amlodipine reduced blood pressure (BP) to the same extent (-28.7 +/- 16.2 mm Hg vs. -26.7 +/- 10.8 mm Hg). In the olmesartan group, DeltaMBF tended to be greater (-0.15 +/- 0.19 ml/g/min vs. 0.03 +/- 0.17 ml/g/min, p = 0.09 by 2-way analysis of variance), and DeltaCVR was significantly decreased (7.9 +/- 23.5 mm Hg/[ml/g/min] vs. -16.6 +/- 18.0 mm Hg/[ml/g/min], p < 0.05) after treatment, whereas these parameters did not change in the amlodipine group (DeltaMBF: -0.15 +/- 0.12 ml/g/min vs. -0.12 +/- 0.20 ml/g/min; DeltaCVR: 6.5 +/- 18.2 mm Hg/[ml/g/min] vs. 4.8 +/- 23.4 mm Hg/[ml/g/min]). Serum SOD activity tended to increase (4.74 +/- 4.77 U/ml vs. 5.57 +/- 4.74 U/ml, p = 0.07 by 2-way analysis of variance) only in the olmesartan group. CONCLUSIONS: Olmesartan, but not amlodipine, improved endothelium-dependent coronary dilation in hypertensive patients independent of BP reduction. These beneficial effects on coronary vasomotion might be via an antioxidant property of ARBs.
PMID: 17868805 [PubMed - indexed for MEDLINE]
保存論文に追加 保存論文に追加

論文ランキング

週間人気論文ランキング - 閲覧数 (2010/03/06/ 09時更新)

The type Ia supernova SNLS-03D3bb from a super-Chandrasekhar-mass white dwarf star.

先週: 3位 rankup 82view,0users 保存 要約を見る 要約

2',5,7-Trihydroxy-4',5'-(2,2-dimethylchromeno)-8-(3-hydroxy-3-methylbutyl) flavanone purified from Cudrania tricuspidata induces apoptotic cell death of human leukemia U937 cells.

先週: 2位 ranksame 76view,0users 保存 要約を見る 要約

Adult satellite cells and embryonic muscle progenitors have distinct genetic requirements.

先週: 1位 rankdown 57view,6users 保存 要約を見る 要約

Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension.

先週: 5位 rankup 53view,4users 保存 要約を見る 要約

A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.

先週: 6位 rankup 53view,2users 保存 要約を見る 要約

RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F.

先週: 4位 rankdown 46view,2users 保存 要約を見る 要約

IL-17A versus IL-17F induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in AGS gastric adenocarcinoma cells.

先週: 7位 ranksame 43view,2users 保存 要約を見る 要約

Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients.

先週: 8位 ranksame 38view,1users 保存 要約を見る 要約

Trypanocidal diarylheptanoids from Aframomum letestuianum.

先週: 9位 ranksame 34view,0users 保存 要約を見る 要約

A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study.

先週: 18位 rankup 34view,22users 保存 要約を見る 要約
※view数:週間 user数:合計